HUMAN INTERLEUKIN-2 |
PROLEUKIN |
INTERLEUKIN-2 ALDESLEUKIN |
ALDESLEUKIN |
INTERLEUKIN 2 |
Drug Categories | lymphokines |
Drug Categories | interleukins |
Drug Class | antineoplastic agents |
Year of Approval | 1992 |
FDA Approval | approved |
Drug Class | recombinant protein |
Drug Indications | antineoplastic agent |
Drug Categories | cytochrome p-450 cyp2e1 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a4 substrates |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | drugs that are mainly renally excreted |
Drug Categories | immunosuppressive agents |
Drug Categories | increased lymphocyte activation |
Drug Categories | increased lymphocyte cell production |
Drug Categories | lymphocyte growth factor |
Drug Categories | narrow therapeutic index drugs |
agonist (activating) |
modulator |
Mechanism of Interaction | Interleukin-2 receptor agonist |
Direct Interaction | yes |
Trial Name | Proleukin IL-2 |
agonist (activating) |
Mechanism of Interaction | Interleukin-2 receptor agonist |
Direct Interaction | yes |
Trial Name | Proleukin IL-2 |
agonist (activating) |
modulator |
Novel drug target | Established target |
Trial Name | Proleukin IL-2 |
Mechanism of Interaction | Interleukin-2 receptor agonist |
ALDESLEUKIN | DrugBank Drug Name |
110942-02-4 | CAS Number |
Proleukin | Drug Brand |
Drug Type | biotech |
Drug Groups | approved |
Drug Categories | adjuvants, immunologic |
ALDESLEUKIN | Primary Drug Name |
Year of Approval | 1992 |
Drug Class | antineoplastic agents |
Drug Indications | antineoplastic agent |
Drug Class | recombinant protein |
FDA Approval | approved |
D05PUD | TTD Drug ID |